Ferguson Wellman Capital Management Inc. Has $9.22 Million Position in Merck & Co., Inc. (NYSE:MRK)

Ferguson Wellman Capital Management Inc. decreased its stake in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 2.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 101,166 shares of the company’s stock after selling 2,731 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $9,223,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Landmark Wealth Management LLC acquired a new position in Merck & Co., Inc. during the 1st quarter worth approximately $25,000. Joseph P. Lucia & Associates LLC acquired a new position in Merck & Co., Inc. during the 1st quarter worth approximately $25,000. Front Row Advisors LLC increased its position in Merck & Co., Inc. by 89.4% during the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after purchasing an additional 160 shares in the last quarter. Okabena Investment Services Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $27,000. Finally, Western Pacific Wealth Management LP acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $29,000. Institutional investors own 73.33% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $87.51 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15. The firm has a fifty day moving average price of $88.83 and a 200-day moving average price of $87.81. Merck & Co., Inc. has a 1 year low of $71.50 and a 1 year high of $95.72. The stock has a market cap of $221.69 billion, a PE ratio of 13.40, a price-to-earnings-growth ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The business had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. During the same quarter last year, the business earned $1.31 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 28.0% compared to the same quarter last year. Equities analysts anticipate that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 42.27%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. UBS Group upped their price target on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the company a “neutral” rating in a research report on Monday, July 18th. Atlantic Securities upped their price target on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Cowen upped their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Finally, SVB Leerink upped their price target on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research report on Monday, September 12th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.28.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.